Premature Luteinization Prevention by GnRH Antagonist in Patients Undergoing IUI

Completed

• Conditions: Infertility
• Interventions: Drug: Ganirelix

• Registration Number: NCT00780858
• Lead Sponsor: IVI Madrid

Brief Summary

Premature luteinization in patients undergoing IUI can occur in up to 24% of cycles. These patients, according to recent data, have a lower pregnancy rate than controls. The possibility to avoid premature luteinization with GnRH antagonist may restore the chances of achieving a pregnancy in these women.

Detailed Description

The purpose of this study was to investigate whether a subset of patients benefits from GnRHa administration during IUI. PL was tested for in patients who were undergoing artificial insemination procedures, and the effect of GnRHa on PR in patients who

Study Timeline

• Study Start: 2008-10
• Study First Submitted: 2008-10-25
• Study First Submitted QC: 2008-10-27
• Study First Posted: 2008-10-28
• Primary Completion: 2010-12
• Study Completion: 2011-03
• Status Verified: 2015-05
• Last Update Submitted: 2015-05-05
• Last Update Posted: 2015-05-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 662

Inclusion Criteria

• previous failed IUI cycle with premature luteinization

Read More

Exclusion Criteria

• 39 years or older
• not eligible for IUI (patent tubes, > 3 million capacitated spermatozoa)
• 4 previous IUI cycles

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Ganirelix	Ganirelix	Patients with premature lutenization (progesterone \>1,2 ng/ml) who did not get pregnant during the first IUI underwent a second IUI.

Primary Outcome Measures

Name	Time	Method
Pregnancy rate	2 weeks after intervention

Secondary Outcome Measures

Name	Time	Method
premature luteinization	at the time of intervention

Trial Locations

Locations (1)

IVI-Madrid; 🇪🇸 Madrid, Spain